The effect of the emerging omicron variant on the willingness to take or continue with COVID-19 vaccination in the Middle East

Tareq L. Mukattash Anan S. Jarab Rana K. Abu-Farha Rania Itani Samar Karout Razan Z. Mansour Shorouq Abuhishmah   

Open Access   

Published:  Apr 23, 2022

DOI: 10.7324/JAPS.2022.121005

The present study aimed to explore the willingness of the general public in the Middle East area to take or continue with the available COVID-19 vaccine in light of the emergence of the new omicron variant. This study is a web-based questionnaire distributed in Lebanon, Jordan, and Kuwait during the omicron variant outbreak. The questionnaire consisted of 15 close-ended questions with predefined options, divided into four sections preceded. The total included responses were 812 that were recruited from Lebanon (n= 427, 52.6%), Jordan (n = 279, 34.4%), and Kuwait (n = 106, 13.1%). Almost two-thirds of the participants (77%) received two doses of the COVID-19 vaccine, while only 7.9% received the booster shot (third dose). On the other hand, 90 participants (11%) did not receive any COVID-19 vaccine yet. The reported willingness among the unvaccinated individuals to receive the COVID-19 vaccine was only 22.4% (20/90). However, higher acceptability of fully vaccinated individuals to receive the booster shot was reported after the surge of the omicron variant (49.2%). The findings of the present study have important implications on COVID-19 vaccination decision. As the pandemic evolves, the public’s opinions with the surge of different variants are changing. Therefore, there is an urgent need to raise awareness about omicron severity, and that the rapidly spreading strain puts the unvaccinated particularly at risk. Vaccine campaigns should elevate the voices of influencing messengers caring for severe COVID-19 cases.

Keyword:     COVID-19 vaccine omicron willingness Middle East.


Mukattash TL, Jarab AS, Abu-Farha RK, Itani R, Karout S, Mansour RZ, Abuhishmah S. The effect of the emerging omicron variant on the willingness to take or continue with COVID-19 vaccination in the Middle East. J Appl Pharm Sci,2022. doi:

Copyright: © The Author(s). This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HTML Full Text


Abu-Farha R, Mukattash T, Itani R, Karout S, Khojah H, AlMahmood A, Alzoubi KH. Willingness of Middle Eastern public to receive COVID-19 Vaccines. Saudi Pharm J, 2021; 29:734-9.

Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, Miller J, Schrag SJ, Verani JR. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and delta variants. JAMA, 2022; 327:639-51.

Aziz AB, Raqib R, Khan WA, Rahman M, Haque R, Alam M, Zaman K, Ross AG. Integrated control of COVID-19 in resource-poor countries. Int J Infect Dis, 2020; 101:98-101.

Chen J, Wang R, Gilby NB, Wei G-W. Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model, 2022; In Press:1-11.

Daniel WW, Cross CL. Biostatistics: a foundation for analysis in the health sciences. 10th edition, 2013.

Feleszko W, Lewulis P, Czarnecki A, Waszkiewicz P. Flattening the curve of COVID-19 vaccine rejection-an international overview. Vaccines, 2021; 9:44.

Garcia-Beltran WF, St Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, Berrios C, Ofoman O, Chang CC, Hauser BM, Feldman J, Roederer AL, Gregory DJ, Poznansky MC, Schmidt AG, Iafrate AJ, Naranbhai V, Balazs AB. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell, 2022; 185:457-66.

Ghosh A, Kar PK, Gautam A, Gupta R, Singh R, Chakravarti R, Ravichandiran V, Dastidar SG, Ghosh D, Roy S. An insight into SARSCoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives. RSC Med Chem, 2022; 1-36.

Government of Canada. Vaccines for COVID-19. CanadaCa, 2022. Available vai coronavirus-disease-covid-19/vaccines.html (accessed 1 March 2022).

Gowrisankar A, Priyanka TMC, Banerjee S. Omicron: a mysterious variant of concern. Eur Phys J Plus, 2022; 137:100.

Al Jazeera. 'Vaccine dictatorship': Many Lebanese refuse the COVID jab 2022. (accessed 2 March 2022).

Jordan Times. Omicron accounts for 90% of daily COVID cases in Kingdom 2022. Available via omicron-accounts-90-daily-covid-cases-kingdom (accessed 3 March 2022).

Kaadan MI, Abdulkarim J, Chaar M, Zayegh O, Keblawi MA. Determinants of COVID-19 vaccine acceptance in the Arab world: a crosssectional study. Glob Heal Res Policy, 2021; 6:23.

Kannan S, Shaik Syed Ali P, Sheeza A. Omicron (B.1.1.529)- variant of concern-molecular profile and epidemiology: a mini review. Eur Rev Med Pharmacol Sci, 2021; 25:8019-22.

Lu L, Mok BW-Y, Chen L-L, Chan JM-C, Tsang OT-Y, Lam BH-S, et al. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. Clin Infect Dis, 2021; ciab1041.

Meo SA, Meo AS, Al-Jassir FF, Klonoff DC. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci, 2021; 25:8012-8.

Middle East Monitor. WHO warns Omicron behind COVID surge across Eastern Mediterranean, 2022. Availble via https://www. (accessed 3 March 2022).

Miller NL, Clark T, Raman R, Sasisekharan R. Insights on the mutational landscape of the SARS-CoV-2 Omicron variant receptorbinding domain. Cell Reports Med, 2022; 3:100527.

Our World in Data. Coronavirus (COVID-19) vaccinations, 2022. Available via (accessed 2 March 2022). Reuters.

Omicron probably caused COVID-19 surge in Mideast in early Jan -WHO official, 2022. Available via world/middle-east/covid-19-cases-surged-mideast-early-jan-deaths-fellwho-official-2022-01-13/ (accessed 3 March 2022).

Singhal T. The emergence of omicron: challenging times are here again! Indian J Pediatr, 2022; 1-7.

Times of India Travel. Kuwait makes COVID-19 booster dose mandatory for travellers, Kuwait. Timestravel, 2021. Available via https://‎mandatory-for-travellers/as88478268.cms (accessed 2 March 2022).

Wang R, Tao L, Han N, Liu J, Yuan C, Deng L, Han C, Sun F, Chi L, Liu M, Liu J. Acceptance of seasonal influenza vaccination and associated factors among pregnant women in the context of COVID-19 pandemic in China: a multi-center cross-sectional study based on health belief model. BMC Pregnancy Childbirth, 2021; 21:745.

World Health Organization. Lebanon: WHO coronavirus disease (COVID-19) dashboard with vaccination data | WHO coronavirus (COVID-19) dashboard with vaccination data.

WHO 2022a. Available via (accessed 3 March 2022).

World Health Organization. Jordan: WHO coronavirus disease (COVID-19) dashboard with vaccination data | WHO coronavirus (COVID-19) dashboard with vaccination data. WHO 2022b. Available via (accessed 3 March 2022).

World Health Organization. Kuwait: WHO coronavirus disease (COVID-19) dashboard with vaccination data | WHO coronavirus (COVID-19) dashboard with vaccination data.

WHO 2022c. Available via (accessed 3 March 2022).

Wu M, Wall EC, Carr EJ. Three-dose vaccination elicits neutralising antibodies against omicron. Lancet Glob Heal, 2022; 399:715-7.

Yadete T, Batra K, Netski DM, Antonio S, Patros MJ, Bester JC. Assessing acceptability of COVID-19 vaccine booster dose among adult americans: a cross-sectional study. Vaccines, 2021; 9:1424.

Zhou Y, Zhang J, Wu W, Liang M, Wu Q-S. Willingness to receive future COVID-19 vaccines following the COVID-19 epidemic in Shanghai, China. BMC Public Health, 2021; 21:1103.

Article Metrics

3 Absract views 31 PDF Downloads 34 Total views

   Abstract      Pdf Download

Related Search

By author names

Citiaion Alert By Google Scholar

Name Required
Email Required Invalid Email Address

Comment required